经颈静脉肝内门体分流术治疗肝硬化并发脾功能亢进症患者疗效研究

doi:10.3969/j.issn.1672-5069.2026.02.029

Abstract

Abstract: Objective The aim of this study was to investigate the clinical effectiveness of transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of patients with liver cirrhosis (LC) and hypersplenism. Methods 62 patients with various etiologies-derived LC were encountered in Shanghai Public Health Clinical Center between March 2021 and August 2023, and all underwent TIPS. Portal pressure gradient (PPG) was measured during the operation, and spleen volume was calculated by uAI Research Portal software based on CT scan. Results The operation was successful in all patients with our series; red blood cell count at presentation was(3.5±0.7)×10¹²/L, it increased to (3.8±0.8)×10¹²/L(P＜0.05) by end of one year follow-up, and hemoglobin was (97.9±23.2)g/L, it increased to(108.9±19.0)g/L by three months, and to (117.4±22.4)g/L(P＜0.05) by end of one-year, while there was no significant changes as respect to white blood cell and platelet counts in our series(P>0.05); liver function test deteriorated in our series during one-year follow-up; the PPG at presentation was (23.3±6.8)mmHg, while it decreased to (8.3±3.5)mmHg after TIPS; before TIPS, the spleen volume was (1039.8±561.9)cm³, it turned to (900.9±489.8)cm³ by end of three-month and to (930.4±589.4)cm³ by end of one-year after TIPS. Conclusion TIPS couldn’t ameliorate hypersplenism, and its role on prevention of varies bleeding is still under observation.

Key words: Liver cirrhosis, Hypersplenism, Transjugular intrahepatic portosystemic shunt, Spleen volume, Therapy

He Yang, Zhang Yijun, Hou Yibin, et al. Clinical effectiveness of transjugular intrahepatic portosystemic shunt in treatment of patients with liver cirrhosis and hypersplenism[J]. Journal of Practical Hepatology, 2026, 29(2): 277-280.

References

[1] Yoshida H, Mamada Y, Taniai N, et al. Partial splenic embolization. Hepatol Res,2010, 38(3):225.
[2] El-Khishen MA, Henderson JM , Millikan WJ ,et al. Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension. Surg Gynecol Obstet, 1985, 160(3):233.
[3] Gibson P R , Gibson R N , Ditchfield M R, et al. Splenomegaly-an insensitive sign of portal hypertension. Aus New Zeal J Med, 2010, 20(6):771-774.
[4] Franchis R D , Bosch J , Garcia-Tsao G ,et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4):959-974.
[5] Kaplan D E , Ripoll C , Thiele M ,et al.AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology, 2023, 79(5):1180-1211.
[6] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-786.
[7] Mitchell O, Feldman DM, Diakow M, et al. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med,2016,8:39-50.
[8] Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol, 2021, 75 (Suppl 1): S67-S81.
[9] 崔文娟,朱凤群.慢性乙型肝炎肝硬化血小板减少影响因素的研究进展.实用肝脏病杂志,2010,13(1):78-80.
[10] Mccormick PA, Docherty JR. Patterns of splenic arterial enhancement on computed tomography scan are related to portal venous hypertension. Eur J Gastroenterol Hepatol, 2020,32(5):623-625.
[11] Bettinger D, Thimme R, Schultheiss M. Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection. Curr Opin Gastroenterol, 2022, 38(3):221-229.
[12] Nicoară-Farcău O, Han G, Rudler M, et al. Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis ofindividual patient data.Gastroenterology,2021,160(1):193-205.
[13] Ashraf P,Shah GM,Shaikh H,et al.Transjugular intrahepatic portosystemic stenting in portal hypertensive gastropathy.J Coll Physicians Surg Pak,2009,19(9):584-585.
[14] Vidal V,Joly L,Perreault P,et al. Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients.Cardiovasc Intervent Radiol, 2006, 29(2): 216-219.
[15] Kamath PS, Lacerda M, Ahlquist DA, et al. Gastric mucosal responses to intrahepatic portosystemic shunting in patients with cirrhosis. Gastroenterology, 2000,118(5):905–911.
[16] Karasu Z , Gurakar A , Kerwin B ,et al. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci, 2000, 45(10):1971-1976.
[17] Lyu Y, Yee Lau W, Wu H, et al. Cause of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly. Exp Biol Med, 2017, 242(7): 744-749.
[18] 陈斯良,肖承江,金思一,等.肝硬化PHTIPS术后血浆脂多糖变化对血小板释放血管内皮生长因子和血小板反应蛋白-1的影响.中华肝脏病杂志,2022,30(2):207-212.
[19] Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol,2008,48:1000-1007.
[20] 周秋娟,朱逸明,马宇航,等.TIPS与PSE术治疗乙型肝炎肝硬化并发脾功能亢进症患者疗效研究.实用肝脏病杂志,2023,26(2):266-269.
[21] Li Y ,Liu Z ,Liu C.Efficacy and safety of laparoscopic splenectomy for hypersplenism secondary to portal hypertension after transjugular intrahepatic portosystemic shunt.BMC Gastroenterol,2021,21(1):61.
[22] Liu J,Ma J,Yang C,et al.Impact of tips on splenic volume and thrombocytopenia. AJR. 2021,216(3).698-703.
[23] Piscaglia F, Zironi G, Gaiani S,et al.Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology, 1999;30(1):58-64.

Clinical effectiveness of transjugular intrahepatic portosystemic shunt in treatment of patients with liver cirrhosis and hypersplenism

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Lingling, Zhang Zhao, Xu Yu. Impacting factors on early virological response in patients with serum HBeAg-negative chronic hepatitis B undergoing pegylated interferon α-2b therapy [J]. Journal of Practical Hepatology, 2026, 29(2): 175-178.
[2]	He Hongmei, Sha Zhihu, Shao Jianguo, et al. Clinical observation of entecavir in combination with Ruangan Sanjie prescription in the treatment of patient with chronic hepatitis B [J]. Journal of Practical Hepatology, 2026, 29(2): 179-182.
[3]	Liu Jing, Liu Tianze, Zhao Chuankui, et al. Antiviral efficacy of sofosbuvir/velpatasvir in the treatment of patients with chronic hepatitis C and concomitant diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2026, 29(2): 195-198.
[4]	Sun Yanjun, Xu Liping, Zhou Ling, et al. A preliminary study on the efficacy of semaglutide in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2026, 29(2): 209-212.
[5]	Zhang Xuhui, Zhang Huipin. Clinical implication of polyreactive IgG levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2026, 29(2): 221-224.
[6]	Zhang Xiaolan, Chen Rui, Chen Min, et al. Clinical feature and risk factors impacting response to immunosuppressive therapy in elderly patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2026, 29(2): 225-228.
[7]	Li Chunyu, Qiu Yuan, Ming Quan. Clinical efficacy of plasma exchange plus sequential double plasma molecular adsorption system in the treatment of patients with hepatitis B virus-associated acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2026, 29(2): 237-240.
[8]	Sun Qin, Jiang Zhenxing, Shao Jianfeng. DPMAS with sequential half-volume plasma exchange in the treatment of patients withhepatitis B virus-associated acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2026, 29(2): 241-244.
[9]	Sun Bohan, Cao Chunli, Qi Lina. Predictive efficacy of serum cystatin C, MELD and ALBI score combination for hepatorenal syndrome-acute kidney injury in patients with decompendated liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(2): 249-252.
[10]	Yue Guodong, Sun Shanfeng, Chang Shujuan, et al. Efficacy of ultrasound shear wave elastography in predicting esophageal variceal bleeding in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(2): 253-256.
[11]	Sun Hengliang, Jiang Haiwei, Zhang Li. Prevalence, pathogens distribution and risk factors of multi-drug resistant bacteria infection in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(2): 257-260.
[12]	Li Junyong, Chen Hua, Huang Yili. Predictive performance of real-time tissue elastography with combination of APRI and FIB-4 for esophageal varices in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2026, 29(2): 261-264.
[13]	Zhou Huimin, Wang Na, Liu Jingjing, et al. Prevalence and risk factors of myocardial injury in patients with liver cirrhosis complicated with esophageal variceal bleeding after endoscopic sclerotherapy [J]. Journal of Practical Hepatology, 2026, 29(2): 265-268.
[14]	Li Yanhui, Zhang Xiaoliang, Li Lanhua. Clinical implication of serum sTREM-1 and PCT levels in patients with decompensated liver cirrhosis complicated with spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2026, 29(2): 269-272.
[15]	Liu Linan, Chang Yufei, Wang Hui. SOFA and MELD-Na scores in predicting prognosis of patients with liver cirrhosis complicated by sepsis [J]. Journal of Practical Hepatology, 2026, 29(2): 273-276.